Verofylline, a methylxanthine bronchodilator, in asthma.
Verofylline, a long-acting polysubstituted methylxanthine bronchodilator, was taken orally by eight adult patients with asthma in a double-blind, crossover tolerance study. Peak expiratory flow, forced vital capacity, and its subdivisions were measured weekly 2, 4, and 6 hr after oral dosing with drug or placebo. Peak drug activity developed between 4 and 6 hr after dosing. Subject tolerance was good at the doses used. Dose-response curves for mean forced expiratory volume in one second, peak expiratory flow rate, and forced expiratory flow at the end of 4 hr were greater after 0.05 mg/kg verofylline than after placebo or higher doses of verofylline. Mean percent change in forced vital capacity remained increased as long as 6 hr after 0.15 mg/kg active drug. Verofylline was not very effective as a bronchodilator at the doses used.
D000284:Administration, Oral; D000328:Adult; D001249:Asthma / Q000188:drug therapy*; D001980:Bronchi / Q000187:drug effects; D001993:Bronchodilator Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008448:Maximal Expiratory Flow Rate; D008450:Maximal Midexpiratory Flow Rate; D008875:Middle Aged; D010366:Peak Expiratory Flow Rate; D013147:Spirometry; D013806:Theophylline / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014797:Vital Capacity
D001993:Bronchodilator Agents; C030126:verofylline; D013806:Theophylline